|
Category: pharmaceuticals / chemical synthisis
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Physical Properties:
| Appearance: | white fine powder (est) |
| Assay: | 95.00 to 100.00 %
|
| Food Chemicals Codex Listed: | No |
| Melting Point: | 213.00 °C. @ 760.00 mm Hg (est)
|
| Boiling Point: | 957.12 °C. @ 760.00 mm Hg (est)
|
| Flash Point: | 991.00 °F. TCC ( 532.60 °C. ) (est)
|
| logP (o/w): | 3.950 (est) |
| Soluble in: |
| | water, 0.004847 mg/L @ 25 °C (est) |
Organoleptic Properties:
| |
| Odor and/or flavor descriptions from others (if found). |
| |
| |
Cosmetic Information:
Suppliers:
Safety Information:
| Preferred SDS: View |
| |
| Hazards identification |
| |
| Classification of the substance or mixture |
| GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) |
| None found. |
| GHS Label elements, including precautionary statements |
| |
| Pictogram | |
| |
| Hazard statement(s) |
| None found. |
| Precautionary statement(s) |
| None found. |
| Oral/Parenteral Toxicity: |
intravenous-dog LDLo 15 mg/kg BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
BEHAVIORAL: ATAXIA
LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION National Technical Information Service. Vol. PB83-170969
intraperitoneal-mouse LD50 128 mg/kg SKIN AND APPENDAGES (SKIN): HAIR: OTHER National Technical Information Service. Vol. PB83-170969
intravenous-mouse LD50 12 mg/kg LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION
BEHAVIORAL: ATAXIA
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) Pharmaceutical Research. Vol. 4, Pg. 162, 1987.
intraperitoneal-rat LD50 32530 ug/kg LUNGS, THORAX, OR RESPIRATION: DYSPNEA
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) National Technical Information Service. Vol. PB83-170969
intravenous-rat LDLo 85 mg/kg LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES
BLOOD: CHANGES IN BONE MARROW NOT INCLUDED ABOVE Journal of Toxicological Sciences. Vol. 19(Suppl
|
| Dermal Toxicity: |
|
Not determined
|
| Inhalation Toxicity: |
|
Not determined
|
Safety in Use Information:
| Category: | pharmaceuticals / chemical synthisis |
| Recommendation for paclitaxel usage levels up to: | | | not for fragrance use.
|
| |
| Recommendation for paclitaxel flavor usage levels up to: |
| | not for flavor use.
|
Safety References:
References:
Other Information:
| (IUPAC): | Atomic Weights of the Elements 2011 (pdf) |
| Videos: | The Periodic Table of Videos |
| tgsc: | Atomic Weights use for this web site |
| (IUPAC): | Periodic Table of the Elements |
| CHEBI: | View |
| CHEMBL: | View |
| KEGG (GenomeNet): | D00491 |
| HMDB (The Human Metabolome Database): | Search |
| Export Tariff Code: | 2932.90.4100 |
| MedlinePlusSupp: | View |
| VCF-Online: | VCF Volatile Compounds in Food |
| ChemSpider: | View |
| Wikipedia: | View |
Formulations/Preparations: •parenteral: for injection, concentrate, for iv infusion: 6 mgml onxol (with dehydrated alcohol 49.7% (vv) and polyoxyl 35 castor oil 527 mgml) (teva), paclitaxel injection (with dehydrated alcohol 49.7% (vv) and polyoxyl 35 castor oil 527 mgml) (bedford, mayne, udl), taxol (with dehydrated alcohol 49.7% (vv) and polyoxyl 35 castor oil 527 mgml) (bristol-myers squibb).
•parenteral: for injectable suspension, for iv infusion: 100 mg (of paclitaxel) abraxane (abraxis). paclitaxel (albumin-bound)
•paclitaxel is commercially available as protein-bound particles consisting of paclitaxel bound to albumin; the mean particle size of albumin-bound paclitaxel is about 130 nm. albumin-bound paclitaxel is a sterile, white to yellow lyophilized powder that must be reconstituted for use as an injectable suspension; there are no solvents. each single-use vial contains 100 mg of paclitaxel and approximately 900 mg of human albumin.
•because paclitaxel is extremely hydrophobic, the commercially available injection concentrate is a sterile, nonaqueous solution of the drug in polyoxyl 35 castor oil (cremophor el, polyoxyethylated castor oil) and dehydrated alcohol. commercially available paclitaxel for injection concentrate is a clear, colorless to slightly yellow, viscous solution. following dilution of paclitaxel for injection concentrate with 5% dextrose and 0.9% sodium chloride injection or 5% dextrose and ringer's injection, solutions containing 0.6 or 1.2 mg of paclitaxel per ml maintain a ph of 4.4-5.6 for up to 27 hours.
|
Potential Blenders and core components note
Potential Uses:
Occurrence (nature, food, other): note
Synonyms:
| | abraxane | | (2a,5b,7b,10b,13a)-4,10-bis( | acetyloxy)-13-{[(2R,3S)-3-(benzoylamino)-2-hydroxy-3-phenylpropanoyl]oxy}-1,7-dihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate | | | anzatax | | | cyclopax | | | ebetaxel | | 5b,20- | epoxy-1,2a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-Diacetate 2-Benzoate 13-Ester with (2R,3S)-N-Benzoyl-3-phenylisoserine | | | genetaxyl | | | genexol | | | intaxel | | | mitotax | | | peclitaxel | | | taxol | | | yewtaxan |
Articles:
| Info: | Taxol |
| PubMed: | Safety and Effectiveness of Bevacizumab-Containing Treatment for Non-Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study. |
| PubMed: | Editorial: plant natural products: inspiring sources for drugs development. |
| PubMed: | PEG-PLA nanoparticles modified with APTEDB peptide for enhanced anti-angiogenic and anti-glioma therapy. |
| PubMed: | Constitutive androstane receptor ligands modulate the anti-tumor efficacy of paclitaxel in non-small cell lung cancer cells. |
| PubMed: | Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. |
| PubMed: | Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy. |
| PubMed: | The Development and Maintenance of Paclitaxel-induced Neuropathic Pain Require Activation of the Sphingosine 1-Phosphate Receptor Subtype 1. |
| PubMed: | Rapid assessment of drug response in cancer cells using microwell array and molecular imaging. |
| PubMed: | Improvement of hairy root cultures and plants by changing biosynthetic pathways leading to pharmaceutical metabolites: Strategies and applications. |
| PubMed: | Systemic toxicity induced by paclitaxel in vivo is associated with the solvent cremophor EL through oxidative stress-driven mechanisms. |
| PubMed: | Antiproliferative and immunostimulatory activity of a protein from Pleurotus eryngii. |
| PubMed: | Comparative effectiveness of adjunctive bevacizumab for advanced lung cancer: the cancer research network experience. |
| PubMed: | Modulation of estrogen and epidermal growth factor receptors by rosemary extract in breast cancer cells. |
| PubMed: | The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials. |
| PubMed: | Metabolic engineering approaches for production of biochemicals in food and medicinal plants. |
| PubMed: | A Targeting Drug Delivery System for Ovarian Carcinoma: Transferrin Modified Lipid Coated Paclitaxel-loaded Nanoparticles. |
| PubMed: | Bioproduction of baccatin III, an advanced precursor of paclitaxol, with transgenic Flammulina velutipes expressing the 10-deacetylbaccatin III-10-O-acetyl transferase gene. |
| PubMed: | Experimentation with inhaled bronchodilators and corticosteroids. |
| PubMed: | U.S. Food and Drug Administration approves paclitaxel protein-bound particles (Abraxane®) in combination with gemcitabine as first-line treatment of patients with metastatic pancreatic cancer. |
| PubMed: | Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. |
| PubMed: | Stent thrombosis with drug-eluting stents: is the paradigm shifting? |
| PubMed: | Combined quantification of paclitaxel, docetaxel and ritonavir in human feces and urine using LC-MS/MS. |
| PubMed: | The US FDAs withdrawal of the breast cancer indication for Avastin (bevacizumab). |
| PubMed: | Outcomes with various drug-eluting or bare metal stents in patients with ST-segment-elevation myocardial infarction: a mixed treatment comparison analysis of trial level data from 34 068 patient-years of follow-up from randomized trials. |
| PubMed: | Exploring a natural MDR reversal agent: potential of medicinal food supplement Nerium oleander leaf distillate. |
| PubMed: | Pharmacokinetic and tissue distribution of paclitaxel in rabbits assayed by LC-UV after intravenous administration of its novel liposomal formulation. |
| PubMed: | Antitumor efficacy of piperine in the treatment of human HER2-overexpressing breast cancer cells. |
| PubMed: | Clinical application of drug delivery systems in cancer chemotherapy: review of the efficacy and side effects of approved drugs. |
| PubMed: | Randomized trial of Legflow(®) paclitaxel eluting balloon and stenting versus standard percutaneous transluminal angioplasty and stenting for the treatment of intermediate and long lesions of the superficial femoral artery (RAPID trial): study protocol for a randomized controlled trial. |
| PubMed: | Synergistic effect of a novel cyclic pentadepsipeptide, neoN-methylsansalvamide, and paclitaxel on human multidrug resistance cancer cell lines. |
| PubMed: | Dynamic cost-effectiveness of oncology drugs. |
| PubMed: | Update on taxane development: new analogs and new formulations. |
| PubMed: | Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. |
| PubMed: | Bevacizumab as first-line therapy in advanced non-small-cell lung cancer: a brazilian center experience. |
| PubMed: | Metastatic melanoma - a review of current and future drugs. |
| PubMed: | Antitumor effect and toxicity of Lipusu in rat ovarian cancer xenografts. |
| PubMed: | Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma. |
| PubMed: | The exposure of highly toxic aconitine does not significantly impact the activity and expression of cytochrome P450 3A in rats determined by a novel ultra performance liquid chromatography-tandem mass spectrometric method of a specific probe buspirone. |
| PubMed: | Overview of the 2011 food and drug administration's circulatory system devices panel of the medical devices advisory committee meeting on the Zilver® PTX® drug-eluting peripheral stent. |
| PubMed: | Determination of morphine, codeine, and paclitaxel in human serum and plasma by micellar electrokinetic chromatography. |
| PubMed: | Taste alteration in breast cancer patients treated with taxane chemotherapy: experience, effect, and coping strategies. |
| PubMed: | The effects of selenium on tumor growth in epithelial ovarian carcinoma. |
| PubMed: | Icariside II potentiates paclitaxel-induced apoptosis in human melanoma A375 cells by inhibiting TLR4 signaling pathway. |
| PubMed: | Cell-type dependent response of melanoma cells to aloe emodin. |
| PubMed: | The use of bevacizumab among women with metastatic breast cancer: a survey on clinical practice and the ongoing controversy. |
| PubMed: | Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. |
| PubMed: | Antiemetic efficacy of single-dose palonosetron and dexamethasone in patients receiving multiple cycles of multiple day-based chemotherapy. |
| PubMed: | Self-assembly and paclitaxel loading capacity of cellulose-graft-poly(lactide) nanomicelles. |
| PubMed: | Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. |
| PubMed: | Periprocedural myocardial infarction in a randomized trial of everolimus-eluting and Paclitaxel-eluting coronary stents: frequency and impact on mortality according to historic versus universal definitions. |
| PubMed: | Ipilimumab: its potential in non-small cell lung cancer. |
| PubMed: | Direct and fast determination of paclitaxel, morphine and codeine in urine by micellar electrokinetic chromatography. |
| PubMed: | A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer. |
| PubMed: | Turmeric (Curcuma longa) inhibits inflammatory nuclear factor (NF)-κB and NF-κB-regulated gene products and induces death receptors leading to suppressed proliferation, induced chemosensitization, and suppressed osteoclastogenesis. |
| PubMed: | Anti-proliferative activity and suppression of P-glycoprotein by (-)-antofine, a natural phenanthroindolizidine alkaloid, in paclitaxel-resistant human lung cancer cells. |
| PubMed: | Bevacizumab in the treatment of metastatic breast cancer: friend or foe? |
| PubMed: | New anti-cancer characteristics of jatrophane diterpenes from Euphorbia dendroides. |
| PubMed: | Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS. |
| PubMed: | Drug-eluting Stents in Acute Coronary Syndrome: Is There a Risk of Stent Thrombosis with Second-Generation Stents? |
| PubMed: | Pharmacokinetic optimization of 4-substituted methoxybenzoyl-aryl-thiazole and 2-aryl-4-benzoyl-imidazole for improving oral bioavailability. |
| PubMed: | Dairy milk fat augments paclitaxel therapy to suppress tumour metastasis in mice, and protects against the side-effects of chemotherapy. |
| PubMed: | Description of anaphylactic reactions to paclitaxel and docetaxel reported to the FDA, with a focus on the role of premedication. |
| PubMed: | Sanguinarine suppresses prostate tumor growth and inhibits survivin expression. |
| PubMed: | Gossypol decreases tumor necrosis factor-α-induced intercellular adhesion molecule-1 expression via suppression of NF-κB activity. |
| PubMed: | Plant-derived bioactive compounds produced by endophytic fungi. |
| PubMed: | Clinical studies with sirolimus, zotarolimus, everolimus, and biolimus A9 drug-eluting stent systems. |
| PubMed: | 18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy. |
| PubMed: | The flavonoid quercetin transiently inhibits the activity of taxol and nocodazole through interference with the cell cycle. |
| PubMed: | Evaluation of the genotoxicity of cisplatin, paclitaxel and 5-fluorouracil combined treatment in the Drosophila wing-spot test. |
| PubMed: | Resveratrol confers resistance against taxol via induction of cell cycle arrest in human cancer cell lines. |
| PubMed: | Reporting of studies on new medicines in major medical journals: a case study in breast cancer. |
| PubMed: | Osthole suppresses fatty acid synthase expression in HER2-overexpressing breast cancer cells through modulating Akt/mTOR pathway. |
| PubMed: | Investigational new drug-directed, 5-day repeat dose toxicity study of 4-[3-(2-nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1, NSC 709257) administered with or without Taxol in Sprague-Dawley rats. |
| PubMed: | Clinically relevant anticancer polymer Paclitaxel therapeutics. |
| PubMed: | Beyond the black box: drug- and device-associated hypersensitivity events. |
| PubMed: | Antiangiogenic agents in the treatment of nonsmall cell lung cancer: reality and hope. |
| PubMed: | [A case of advanced gastric cancer that a medical therapy effect was provided grade 3 by a histopathological diagnosis after long-term chemotherapy]. |
| PubMed: | Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells. |
| PubMed: | Development and validation of a stability-indicating method for the quantitation of Paclitaxel in pharmaceutical dosage forms. |
| PubMed: | Management of metastatic breast cancer: monotherapy options for patients resistant to anthracyclines and taxanes. |
| PubMed: | Ovarian cancer (advanced). |
| PubMed: | [Acceptable safety of bevacizumab therapy in combination with chemotherapy in patients with advanced lung cancer.]. |
| PubMed: | Symptom management in patients with cancer of the female reproductive system receiving chemotherapy. |
| PubMed: | The mouse lymphoma assay detects recombination, deletion, and aneuploidy. |
| PubMed: | Analysis of cell cycle phases and proliferative capacity in mice bearing melanoma maintained on different dietary proteins. |
| PubMed: | Discovery of ixabepilone. |
| PubMed: | IL-13 cytotoxin has potent antitumor activity and synergizes with paclitaxel in a mouse model of oral squamous cell carcinoma. |
| PubMed: | Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel meeting on the Xience V Everolimus-Eluting Coronary Stent. |
| PubMed: | Evolution of bevacizumab-based therapy in the management of breast cancer. |
| PubMed: | Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. |
| PubMed: | Endothelial cell recovery between comparator polymer-based drug-eluting stents. |
| PubMed: | A three-year survivor case of gastric cancer with peritoneal dissemination--an outpatient with second-line weekly paclitaxel. |
| PubMed: | Coronary artery stents: Part I. Evolution of percutaneous coronary intervention. |
| PubMed: | Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer. |
| PubMed: | Effect of food on the pharmacokinetic behavior of the potent oral taxane BMS-275183. |
| PubMed: | Epothilones: clinical update and future directions. |
| PubMed: | Cordyceps sinensis health supplement enhances recovery from taxol-induced leukopenia. |
| PubMed: | [Drug-eluting stent thrombosis and its pharmacological prevention]. |
| PubMed: | Taxanes from Shells and Leaves of Corylus avellana. |
| PubMed: | Transformation of bioactive compounds by Fusarium sacchari fungus isolated from the soil-cultivated ginseng. |
| PubMed: | Effect of the bioactive metabolite euplotin C on phagocytosis and fluid-phase endocytosis in the single-celled eukaryote Paramecium. |
| PubMed: | Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. |
| PubMed: | Litchi flavonoids: isolation, identification and biological activity. |
| PubMed: | FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. |
| PubMed: | Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. |
| PubMed: | Pathology of drug-eluting stents: implications for coronary intervention. |
| PubMed: | Unanswered questions--drug-eluting stents and the risk of late thrombosis. |
| PubMed: | New, expanded, and modified use of approved antineoplastic agents in ovarian cancer. |
| PubMed: | Second-line treatment of small-cell lung cancer. |
| PubMed: | Immunomodulatory and anticancer activities of flavonoids extracted from litchi (Litchi chinensis Sonn) pericarp. |
| PubMed: | A recombinant human RNASET2 glycoprotein with antitumorigenic and antiangiogenic characteristics: expression, purification, and characterization. |
| PubMed: | [Successful treatment of an elderly patient with advanced gastric cancer using low-doses of 5-fluorouracil, levofolinate calcium, and cis-platinum with chronomodulation]. |
| PubMed: | Evaluation of paclitaxel rearrangement involving opening of the oxetane ring and migration of acetyl and benzoyl groups. |
| PubMed: | Nanoparticle albumin-bound paclitaxel for treatment of metastatic breast cancer. |
| PubMed: | Off-label use: an industry perspective on expanding use beyond approved indications. |
| PubMed: | Clinical evidence on polymer-based sirolimus and paclitaxel eluting stents. |
| PubMed: | The role of capecitabine in first-line treatment for patients with metastatic breast cancer. |
| PubMed: | Ongoing in vivo studies with cytoskeletal drugs in tau transgenic mice. |
| PubMed: | Second-line treatment for advanced-stage non-small-cell lung cancer: current and future options. |
| PubMed: | Large-scale purification of 13-dehydroxybaccatin III and 10-deacetylpaclitaxel, semi-synthetic precursors of paclitaxel, from cell cultures of Taxus chinensis. |
| PubMed: | Determination of docetaxel and Paclitaxel in human plasma by high-performance liquid chromatography: validation and application to clinical pharmacokinetic studies. |
| PubMed: | Clinical features and correlates of gemcitabine-associated lung injury: findings from the RADAR project. |
| PubMed: | Impact of a scientific presentation on community treatment patterns for primary breast cancer. |
| PubMed: | Sirolimus and Paclitaxel on polymer-based drug-eluting stents: similar but different. |
| PubMed: | [A case of recurrent gastric cancer with peritoneal dissemination successfully treated over 1 year 8 months with combined chemotherapy of paclitaxel and TS-1]. |
| PubMed: | Co-treatment with grapefruit juice inhibits while chronic administration activates intestinal P-glycoprotein-mediated drug efflux. |
| PubMed: | Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. |
| PubMed: | Second- and third-line treatments in non-small cell lung cancer. |
| PubMed: | Adjuvant chemotherapy for early breast cancer: optimal use of epirubicin. |
| PubMed: | Topotecan: weighing in when there are many options. |
| PubMed: | Bypassing Bypass Surgery and Other Success Stories from the National Institutes of Health. |
| PubMed: | The World Health Organization's prequalification program and its potential effect on data exclusivity laws. |
| PubMed: | Docetaxel in the management of ovarian cancer. |
| PubMed: | A sesquiterpenelactone from Inula britannica induces anti-tumor effects dependent on Bcl-2 phosphorylation. |
| PubMed: | Cardiovascular device development: drug-eluting stents and implantable devices for the treatment of heart failure--the view from the Circulatory System Advisory Panel. |
| PubMed: | Capecitabine: a review. |
| PubMed: | Development of docetaxel in advanced non-small-cell lung cancer. |
| PubMed: | Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-kappaB and the serine/threonine kinase Akt and is independent of tubulin polymerization. |
| PubMed: | Polymer-based paclitaxel-eluting stents in percutaneous coronary intervention: a review of the TAXUS trials. |
| PubMed: | Problems with drug-eluting coronary stents--the FDA perspective. |
| PubMed: | Chemoradiation therapy is effective for the palliative treatment of malignant dysphagia. |
| PubMed: | FDA approves Taxus stent; materials managers cheer. |
| PubMed: | United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. |
| PubMed: | Patent infringement. Court denies motion to alter patent claim decision. |
| PubMed: | New agents in the treatment of small-cell lung cancer: focus on gemcitabine. |
| PubMed: | Combined effects of resveratrol and paclitaxel on lung cancer cells. |
| PubMed: | Drug-eluting stents substantially lower rate of restenosis. |
| PubMed: | FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. |
| PubMed: | Weekly paclitaxel for a patient with advanced gastric cancer. |
| PubMed: | Current therapies in ovarian cancer. |
| PubMed: | Antiproliferative activity of apples is not due to phenolic-induced hydrogen peroxide formation. |
| PubMed: | Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. |
| PubMed: | Campylobacter fetus adheres to and enters INT 407 cells. |
| PubMed: | A third-generation matrix metalloproteinase (MMP) inhibitor (ONO-4817) combined with docetaxel suppresses progression of lung micrometastasis of MMP-expressing tumor cells in nude mice. |
| PubMed: | From taxol to Taxol: the changing identities and ownership of an anti-cancer drug. |
| PubMed: | Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma. |
| PubMed: | Gemcitabine-based therapy in pancreas cancer: gemcitabine-docetaxel and other novel combinations. |
| PubMed: | Recent advances in the treatment of AIDS-related Kaposi's sarcoma. |
| PubMed: | Trastuzumab/chemotherapy combinations in metastatic breast cancer. |
| PubMed: | Docetaxel for locally advanced or metastatic non-small-cell lung cancer. Current data and future directions as front-line therapy. |
| PubMed: | New drugs in gynecologic cancer. |
| PubMed: | HER-2/Neu overexpression does not predict response to neoadjuvant chemotherapy or prognosticate survival in patients with locally advanced breast cancer. |
| PubMed: | The effect of paclitaxel on gene expression and activity of arylamine N-acetyltransferase and DNA-2-aminofluorene adduct formation in human leukemia HL-60 cells. |
| PubMed: | The effect of paclitaxel on 2-aminofluorene-DNA adducts formation and arylamine N-acetyltransferase activity and gene expression in human lung tumor cells (A549). |
| PubMed: | FDA: approval of generic drug reversed by U.S. Court of Appeals. |
| PubMed: | Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer. |
| PubMed: | Monte Carlo docking simulations of cyclomaltoheptaose and dimethyl cyclomaltoheptaose with paclitaxel. |
| PubMed: | Drug combination approved for advanced breast cancer. |
| PubMed: | Inhibitory effect of tumor cell proliferation and induction of G2/M cell cycle arrest by panaxytriol. |
| PubMed: | Novel polyphenol molecule isolated from licorice root (Glycrrhiza glabra) induces apoptosis, G2/M cell cycle arrest, and Bcl-2 phosphorylation in tumor cell lines. |
| PubMed: | From the Food and Drug Administration. |
| PubMed: | What ever happened to...? Looking back 10 years. |
| PubMed: | A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. |
| PubMed: | Paclitaxel for treating KS. |
| PubMed: | Low-dose paclitaxel effective in advanced KS. |
| PubMed: | Inter-species differences in drug properties. |
| PubMed: | Clinical pharmacokinetics of capecitabine. |
| PubMed: | Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. |
| PubMed: | Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer. |
| PubMed: | Nanospheres of biodegradable polymers: a system for clinical administration of an anticancer drug paclitaxel (Taxol). |
| PubMed: | New therapies for the treatment of AIDS-related Kaposi sarcoma. |
| PubMed: | [Evidenced-based medicine and future direction of Taxol]. |
| PubMed: | Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. |
| PubMed: | Chemotherapy for advanced hormone refractory prostate cancer. |
| PubMed: | Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916. |
| PubMed: | The mycotoxin patulin induces intra- and intermolecular protein crosslinks in vitro involving cysteine, lysine, and histidine side chains, and alpha-amino groups. |
| PubMed: | FDA advisors recommend approval of taxol for node-positive breast cancer. |
| PubMed: | Cancer chemotherapy, biodiversity, public and private property: the case of the anti-cancer drug taxol. |
| PubMed: | Fluoropyrimidines: a critical evaluation. |
| PubMed: | Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. |
| PubMed: | Treatment of refractory and recurrent ovarian cancer. |
| PubMed: | Tour de paclitaxel: biocatalysis for semisynthesis. |
| PubMed: | Oral 5-FU analogues in the treatment of breast cancer. |
| PubMed: | Clinical status and optimal use of topotecan. |
| PubMed: | Predicting drug interactions in vivo from experiments in vitro. Human studies with paclitaxel and ketoconazole. |
| PubMed: | Colchicine down-regulates lipopolysaccharide-induced granulocyte-macrophage colony-stimulating factor production in murine macrophages. |
| PubMed: | Docetaxel and gemcitabine released for cancer chemotherapy. |
| PubMed: | Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer: from advanced disease to adjuvant therapy. |
| PubMed: | Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene. |
| PubMed: | A preliminary risk-benefit assessment of paclitaxel. |
| PubMed: | USA update on paclitaxel in ovarian cancer. |
| PubMed: | Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences. |
| PubMed: | Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. |
| PubMed: | [Reproductive and developmental toxicity studies of paclitaxel. (III)--Intravenous administration to rats during the perinatal and lactation periods]. |
| PubMed: | [Reproductive and developmental toxicity studies of paclitaxel. (II)--Intravenous administration to rats during the fetal organogenesis]. |
| PubMed: | [Reproductive and developmental toxicity studies of paclitaxel. (I)--Intravenous administration to rats prior to and in the early stages of pregnancy]. |
| PubMed: | [Toxicity studies of paclitaxel. (II)--One-month intermittent intravenous toxicity in rats]. |
| PubMed: | Taxol induces the hematopoietic growth factor granulocyte-macrophage colony-stimulating factor in murine B-cells by stabilization of granulocyte-macrophage colony-stimulating factor nuclear RNA. |
| PubMed: | Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. |
| PubMed: | New therapeutic agents marketed in 1993. |
| PubMed: | From the Food and Drug Administration. |
| PubMed: | Patient care issues: the management of paclitaxel-related toxicities. |
| PubMed: | Isolation, structural determination, and biological activity of 6 alpha-hydroxytaxol, the principal human metabolite of taxol. |
| PubMed: | Effect of cimetidine, probenecid, and ketoconazole on the distribution, biliary secretion, and metabolism of [3H]taxol in the Sprague-Dawley rat. |
| PubMed: | Nursing implications in the administration of paclitaxel (TAXOL). |
| PubMed: | Clinical development of Taxol. |
| PubMed: | Steady-state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer. |
| PubMed: | FDA approves treatment IND protocol for taxol. |
| PubMed: | From the Food and Drug Administration. |
| PubMed: | Drugs affecting microtubule dynamics increase alpha-tubulin mRNA accumulation via transcription in Tetrahymena thermophila. |
|